{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:30:31Z","timestamp":1786984231066,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Although several biomarkers can predict human papillomavirus (HPV) status in head and neck squamous cell carcinoma (HNSC), their accuracy is low. We assessed the HPV status of HNSC using a Scissor algorithm in conjunction with bulk sequencing and single-cell sequencing data. A Scissor scoring system was constructed for predicting HPV status using the gene set variation analysis algorithm. The biological functions and signaling pathways influencing the Scissor scoring model were described using correlation analysis and functional annotation. We used the Scissor algorithm to identify 1070 HPV-positive cells in single-cell sequencing data based on HPV status and then screened out genes that were significantly expressed in the Scissor-positive cells. We then constructed a Scissor score model using the 43 genes specifically expressed in Scissor-positive cells. The model had high accuracy in predicting HPV status in HNSC patients (area under curve in the discovery set: 86.6%, area under curve in the validation set: 96.1% and 79.8%). We also found that patients with higher Scissor scores had better outcomes, higher tumor mutational burden and tumor neoantigen burden, higher levels of immune checkpoint infiltration, and more cytotoxic T cell infiltration, and better outcomes with radiotherapy and immunotherapy. We constructed a predictive model that can accurately predict HPV status in patients with HNSC with greater accuracy than most current biomarkers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050218","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:01:58Z","timestamp":1786730518000},"page":"e50218","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Identifying head and neck squamous cell carcinoma"],"prefix":"10.1097","volume":"105","author":[{"given":"Haihong","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital, Jingmen, Hubei, China"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital Affiliated to Jingchu University of Technology, Jingmen, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital, Jingmen, Hubei, China"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital Affiliated to Jingchu University of Technology, Jingmen, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital, Jingmen, Hubei, China"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital Affiliated to Jingchu University of Technology, Jingmen, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kepeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital, Jingmen, Hubei, China"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital Affiliated to Jingchu University of Technology, Jingmen, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5109-8218","authenticated-orcid":false,"given":"Yuhui","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital, Jingmen, Hubei, China"},{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Jingmen Central Hospital Affiliated to Jingchu University of Technology, Jingmen, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1078-0432.CCR-20-0557","article-title":"Integrative analysis of miRNAs identifies clinically relevant epithelial and stromal subtypes of head and neck squamous cell carcinoma.","volume":"27","author":"Holt","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"e145488","DOI":"10.1172\/JCI145488","article-title":"Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma.","volume":"131","author":"Koyuncu","year":"2021","journal-title":"J Clin Invest"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma.","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2019.11.014","article-title":"Immune landscape of viral- and carcinogen-driven head and neck cancer.","volume":"52","author":"Cillo","year":"2020","journal-title":"Immunity"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","article-title":"Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.","volume":"39","author":"Huang","year":"2021","journal-title":"Cancer Cell"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/vim.2017.0119","article-title":"Eradicating HPV-associated cancer through immunization: a glass half full\u2026.","volume":"31","author":"Frazer","year":"2018","journal-title":"Viral Immunol"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1078-0432.CCR-21-3151","article-title":"Cell-free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.","volume":"28","author":"Siravegna","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41598-021-04307-3","article-title":"Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer.","volume":"12","author":"Akashi","year":"2022","journal-title":"Sci Rep"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1158\/1078-0432.CCR-19-2384","article-title":"HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA.","volume":"27","author":"Leung","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma.","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41591-019-0736-4","article-title":"Single-cell genomic approaches for developing the next generation of immunotherapies.","volume":"26","author":"Yofe","year":"2020","journal-title":"Nat Med"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41587-021-01091-3","article-title":"Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data.","volume":"40","author":"Sun","year":"2022","journal-title":"Nat Biotechnol"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002).","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.annonc.2022.03.005","article-title":"Genetic variation within the human papillomavirus type 16 genome is associated with oropharyngeal cancer prognosis.","volume":"33","author":"Lang Kuhs","year":"2022","journal-title":"Ann Oncol"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-20-3596","article-title":"Deep learning predicts HPV association in oropharyngeal squamous cell carcinomas and identifies patients with a favorable prognosis using regular H&E stains.","volume":"27","author":"Klein","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-14-2481","article-title":"Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.","volume":"21","author":"Keck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma.","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1002\/ijc.29649","article-title":"The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.","volume":"137","author":"Wichmann","year":"2015","journal-title":"Int J Cancer"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"e007823","DOI":"10.1136\/jitc-2023-007823","article-title":"Association of a gene-expression subtype to outcome and treatment response in patients with recurrent\/metastatic head and neck squamous cell carcinoma treated with nivolumab.","volume":"12","author":"Serafini","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-021-21043-4","article-title":"Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution.","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data.","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer.","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters.","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/hed.24531","article-title":"Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent\/residual oropharyngeal carcinoma: a systematic review and meta-analysis.","volume":"38","author":"Jayaram","year":"2016","journal-title":"Head Neck"},{"key":"R28-20260817","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer.","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"R29-20260817","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R30-20260817","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R31-20260817","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R32-20260817","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"R33-20260817","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"R34-20260817","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:00:51Z","timestamp":1786982451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050218"}},"subtitle":["HPV-associated signature by integrating bulk and single-cell sequencing data"],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":34,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050218","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2024-10-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}